Top stories from TTO's February newsletter:
Event: Entrepreneurship Under the Microscope
Recap + Video: "Inside The Black Box"
GlobeImmune Tests New Cancer Drug
Drug and vaccine research company GlobeImmune Inc. is testing its new GI-6301 Tarmogen cancer drug in a study funded by the National Cancer Institute. The GI-6401 Tarmogen product is used for patients with metastatic cancers containing brachyury protein.
Valeant Pharmaceuticals to Take Over Eyetech
Valeant Pharmaceuticals recently agreed to acquire Eyetech, a privately owned ophthalmic biotechnology company. Eyetech currently markets Macugen® in the U.S., the first anti-VEGF inhibitor approved for wet age-related macular degeneration (AMD) that was developed at CU.
CU Study Details On-Off Switch for Breast Cancer
Signals can tell cells to act cancerous, surviving, growing and reproducing out of control. And signals can also tell cells with cancerous characteristics to stop growing or to die. In breast cancer, one tricky signal called TGF-beta does both - sometimes promoting tumors and sometimes suppressing them. A study recently published by CU Denver researcher Heide Ford details how tumors may flip the TGF-beta signalling switch, allowing doctors to delete the pathway entirely when it promotes tumors, and leave it intact when it's still working to suppress them. (Learn more about this research program.)
Read the full newsletter, or sign up to receive a monthly email update.
6 hours ago
No comments:
Post a Comment